Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?
In this article, an approach to the diagnostic evaluation of patients with newly diagnosed advanced NSCLC is suggested, in an attempt to identify the best treatment options. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Apar Kishor Ganti, MD, MS Source Type: news

Time Is Up for PD-L1 Testing Standardization in Lung Cancer Time Is Up for PD-L1 Testing Standardization in Lung Cancer
Rapid efforts are needed to determine analytical concordance between PD-L1 assays.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Phase 1/2 clinical trial in patients with advanced solid tumors that have progressed on anti-PD-1/PD-L1 therapy to evaluate APX005M in combination with cabiralizumab and Opdivo Study to enroll metastatic non-small cell lung cancer (NSCLC), metastatic me... Biopharmaceuticals, Oncology Apexigen, cabiralizumab, Opdivo, NSCLC, melanoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2018 Category: Pharmaceuticals Source Type: news

Treating intestine with ‘good’ cholesterol compound inhibits lung tumor growth in mice
FINDINGSA compound that mimics the main protein in high-density lipoprotein (HDL, or “good”) cholesterol significantly reduced the number of tumors in the lungs of mice, reports a team of UCLA researchers. The findings help explain the connection between HDL cholesterol and reduced cancer risk, and suggest that a similar compound may be an effective therapy in humans.BACKGROUNDPrevious research, both in lab animals and humans, had suggested that higher HDL cholesterol levels were linked to reduced cancer risk. The team ’s earlier work had found that small peptide “mimetics,” or mimics, of...
Source: UCLA Newsroom: Health Sciences - June 13, 2018 Category: Universities & Medical Training Source Type: news

We Can't Find Lung Cancer if We Don't Look for It We Can't Find Lung Cancer if We Don't Look for It
Use of low-dose CT lags far behind use of other cancer screening tests.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2018 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Many Canadians diagnosed with colorectal cancer too late, despite availability of screening
Colorectal cancer is the second-most deadly type in Canada, after lung cancer, but many of those lives could be saved through screening, new statistics suggest. (Source: CBC | Health)
Source: CBC | Health - June 13, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Sensitive to Smoke, Lung Cancer Gene
Title: Sensitive to Smoke, Lung Cancer GeneCategory: Doctor's& Expert's views on SymptomsCreated: 7/27/2004 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:09 PM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - June 13, 2018 Category: Respiratory Medicine Source Type: news

Intuitive Surgical drops $15m, inks collab dev and licensing deal in Broncus Medical Series A
Broncus Medical said today it raised $15 million in a Series A from robotic surgery giant Intuitive Surgical (NSDQ:ISRG). The investment comes in three parts, including the $15 million equity investment, a technology development collaborative agreement and a licensing deal that will put Broncus Medical’s intellectual properties in Sunnyvale, Calif.-based Intuitive’s hands. Broncus Medical is developing technologies focused on diagnostic and therapeutic lung procedures, and will use funds from the round to support continued development of its lung cancer tech, including clinical trials. The company is curre...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging Respiratory Broncus Medical Intuitive Surgical Source Type: news

Cell-Free DNA Blood Test May Detect Early-Stage Lung Cancer
Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Geoffrey Oxnard, MD Source Type: news

ACR responds to USPSTF CT lung screening research plan
The American College of Radiology (ACR) and various partner associations have...Read more on AuntMinnie.comRelated Reading: ACR touts merits of CT colonography for screening ACR Foundation doles out global humanitarian award ACR asks CMS to clarify CT lung cancer screening payment ACR names McGinty as new chair ACR points out reasons for low CT lung screening rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 11, 2018 Category: Radiology Source Type: news

Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma. In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models. “This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Dui...
Source: Asbestos and Mesothelioma News - June 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Air pollution may be causing more people to commit petty crimes
(Natural News) Air pollution is known for negatively impacting the lives of many. It causes several health problems such as increasing the risk of heart disease, stroke, lung cancer, and respiratory issues. More than that, it’s really bad for the environment. But recently, another adverse effect of air pollution was added to the list. In... (Source: NaturalNews.com)
Source: NaturalNews.com - June 11, 2018 Category: Consumer Health News Source Type: news

PARP inhibitor improves overall response rates in small cell lung cancer patients
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients -- those whose tumors expressed SLFN11 -- who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 11, 2018 Category: International Medicine & Public Health Source Type: news

Next-Gen Sequencing for Lung Cancer: Do It Early, for All Next-Gen Sequencing for Lung Cancer: Do It Early, for All
Dr Mark Kris talks about the advantages of next-gen sequencing, from obtaining valuable bioinformatics to detecting rare abnormalities.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Smoking-Related Lung Cancer Remains Elevated 25 Years After Quitting
Among former heavy smokers, the risk for lung cancer remains significantly increased compared with never-smokers, even more than 25 years since quitting. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Impact and Implications of Lung Cancer Screening
In this video at ASCO 2018,James Mulshine, MD, discusses CMS coverage of low-dose CT lung cancer screening for selected Medicare beneficiaries, and clinical implications of early detection. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2018 Category: Cancer & Oncology Authors: James Mulshine, MD Source Type: news

Treatment Advances Give Hope to People with Brain Metastases
Treatment TermsMetastatic Brain and Spine Tumors Author Erin Hull Overview Lisa VanTress didn ’t know why she couldn’t regain her land legs after a 13-hour fishing trip in the summer of 2016. When the dizziness caused her to stumble and fall, she went to the emergency room. She soon learned she had lung cancer that had spread to her brain. Hero Imagebrainmets1932x862.jpg Preview Image Content Blocks CTA Header Learn More CTA ButtonBrain and Spine Metastases Patient Name Lisa VanTress Patient Photo Featured Doctors Peter E. Fecci, MD, PhD Jeffrey Melson Clarke, MD Scott R. Floyd, MD, PhD Relate...
Source: dukehealth.org: Duke Health News - June 8, 2018 Category: Consumer Health News Authors: efh7 at duke.edu Source Type: news

Are we using the right metrics for CT lung screening?
CT lung cancer screening has been shown to reduce mortality when administered...Read more on AuntMinnie.comRelated Reading: 3 steps to personalized CT lung cancer screening ASCO: CT lung cancer screening rates continue to stagnate Risk-based CT lung screening could be more efficient USPSTF opens review of CT lung screening guidance Lung cancer risk model optimizes follow-up CT screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 8, 2018 Category: Radiology Source Type: news

$8.1 million grant funds new center to research highly aggressive form of lung cancer
(Vanderbilt University) A five-year National Cancer Institute grant will fund an interdisciplinary research center at Vanderbilt for the study of small cell lung cancer, a highly aggressive, incurable form of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 8, 2018 Category: Cancer & Oncology Source Type: news

Weekly Online Symptoms Survey Linked to Prolonged OS in Lung Cancer
Bryant FurlowJun 7, 2018Weekly patient symptom self-reports, filed using an online tool, allowed timely detection of lung cancer relapses and prolonged patient survival. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Lung cancer drug likely to be approved for wider NHS use
NICE set to approve greater use of pembrolizumab Related items fromOnMedica First new cancer drug introduced under Cancer Drugs Fund Cigars and pipes raise mortality risk independent of cigarettes Public drastically underestimates cannabis risks Erlotinib prolongs survival in lung cancer New targeted drug could help treat advanced cancers (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 7, 2018 Category: UK Health Source Type: news

Lung cancer immunotherapy drug to be available on the NHS
NHS England has agreed with pharmaceutical company MSD to make the lung cancer drug pembrolizumab available for routine use on the NHS. (Source: NHS Networks)
Source: NHS Networks - June 7, 2018 Category: UK Health Source Type: news

ASCO: New Assays May Detect Early Lung Cancer in Blood
WEDNESDAY, June 6, 2018 -- Three assays may detect early lung cancer in blood samples using genome sequencing, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2018 Category: Pharmaceuticals Source Type: news

Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study
Adding atezolizumab to a combination of bevacizumab, carboplatin and paclitaxel gives patients with metastatic nonsquamous non-small-cell lung cancer better odds of progression-free and overall survival, a new study of 692 patients with wild-type disease has concluded.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Philips Bets Big on Image-Guided Therapy with Latest Acquisition
Royal Philips is seeking to expand its image-guided therapy solutions with the acquisition EPD Solutions. Philips is set to acquire the Tortola, British Virgin Islands-based company for about $292 million upfront. The deal could close in July, Philips said. EPD’s cardiac imaging and navigation system has received CE mark and is used in diagnostic and therapeutic procedures for cardiac arrhythmias. The system has not been given a nod from FDA and is currently under review by the agency. Philips said its interventional imaging systems, such as Azurion, and EPD’s cardiac imaging and navigation system could more ef...
Source: MDDI - June 5, 2018 Category: Medical Devices Authors: Omar Ford Tags: Imaging Cardiovascular Source Type: news

Steroids Diminish Survival Benefits From ICIs in Lung Cancer
Bryant FurlowJun 5, 2018Corticosteroid medications are associated with poorer outcomes of therapy with immune checkpoint inhibitors for patients with lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
New approval based on KEYNOTE-021, Cohort G1, results INDIANAPOLIS, June 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a ... Biopharmaceuticals, Oncology, FDA Eli Lilly, ALIMTA, pemetrexed, KEYTRUDA, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2018 Category: Pharmaceuticals Source Type: news

For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds
In findings that may allow many lung cancer patients to avoid chemotherapy, a large clinical trial has shown that the immunotherapy drug Keytruda is a more effective initial treatment for two-thirds of patients with the most common type of lung cancer.Compared with advanced small-cell lung cancer... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - June 5, 2018 Category: Science Authors: Melissa Healy Source Type: news

Are PCPs Really Doing a Bad Job of Screening for Lung Cancer? Are PCPs Really Doing a Bad Job of Screening for Lung Cancer?
Lung cancer screening rates in the United States are low. Is that necessarily bad?Georgetown University Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 4, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news

Many Breast Cancer Patients Can Safely Skip Chemo, Major Study Finds
CHICAGO (CBS News/AP) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most wo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 4, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer Chemotherapy Source Type: news

Merck's Keytruda shows promise in treating advanced melanoma
(Reuters) - Merck& Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment. (Source: Reuters: Health)
Source: Reuters: Health - June 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC
MONDAY, June 4, 2018 -- For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

Could a Blood Test Spot Lung Cancer Early?
Title: Could a Blood Test Spot Lung Cancer Early?Category: Health NewsCreated: 6/2/2018 12:00:00 AMLast Editorial Review: 6/4/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 4, 2018 Category: Cancer & Oncology Source Type: news

On the search for new approaches to cure lung cancer
(Johannes Gutenberg Universitaet Mainz) Protein kinases regulate nearly all processes in cells. If the function of these enzymes is disrupted, often cancer will develop. In particular certain types of deregulated mitogen-activated protein kinases (MAPKs) are believed to be the cause of various types of cancer. In his new research project, cellular biologist Professor Krishnaraj Rajalingam of the Mainz University Medical Center intends to dissect on the molecular level how disturbed MAPKs lead to the generation of tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

PharmaMar presents new results with lurbinectedin
(Pharmamar) PharmaMar (MSE:PHM) today announced new data on the recurrent small-cell lung cancer patients cohort of the phase II basket study with lurbinectedin as a single agent, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting, being held from the 1st to the 5th of June in Chicago. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Roche reports disappointing cancer trials
Two Roche oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 3, 2018 Category: Pharmaceuticals Source Type: news

Alectinib Outperforms Crizotinib in ALK+ Lung Cancer
Bryant FurlowJun 3, 2018Alectinib was generally better tolerated and associated with better outcomes vs crizotinib in ALK mutation –positive non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

' End of an Era' for Chemo in Non-Small Cell Lung Cancer'End of an Era' for Chemo in Non-Small Cell Lung Cancer
The fear of unsupportable adverse effects from chemotherapy can be laid to rest for most patients with non-small cell lung cancer, say experts at the world's largest cancer meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival
Bryant FurlowJun 3, 2018Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Is Pembrolizumab Appropriate Before EGFR TKI Therapy in Lung Cancer?
Bryant FurlowJun 3, 2018Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Merck's Keytruda extends lung cancer survival in two trials
CHICAGO (Reuters) - Merck& Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck Wins Again
" As we had imagined and hoped, Keytruda has proved to be foundational for the treatment of lung cancer, " says Roger Perlmutter, the research head at Merck. " The question that will be addressed by oncologists of the future will be: In which individuals does one decide to use monotherapy Keytruda? " (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 3, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:MRK NYSE:BMY NYSE:AZN Source Type: news

Detecting Lung Cancer From Simple Blood Draw Detecting Lung Cancer From Simple Blood Draw
Two years ago it was a'pipe dream', but a new study show that a simple blood test for circulating tumor DNA can detect lung cancer; the dream inches ever closer to becoming a reality.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Most Women With Breast Cancer Can Skip Chemo, According to New Study
(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this ...
Source: TIME: Health - June 3, 2018 Category: Consumer Health News Authors: Marilynn Marchione / AP Tags: Uncategorized healthytime onetime Women's Health Source Type: news

Most Women With Breast Cancer Can Skip Chemo, According to New Study
(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this ...
Source: TIME: Science - June 3, 2018 Category: Science Authors: Marilynn Marchione / AP Tags: Uncategorized healthytime onetime Women's Health Source Type: news

Merck's Keytruda shown to extend lung cancer survival in two trials
CHICAGO (Reuters) - New trial results show that Merck& Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard-to-treat squamous cell lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck cements its position as dominant developer of immunotherapy
Patients taking group’s lung cancer drug lived longer than those on chemotherapy (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - June 3, 2018 Category: Pharmaceuticals Source Type: news

Cancer Drug Keytruda a New Weapon Against Advanced Lung Tumors
SUNDAY, June 3, 2018 -- A cancer drug that boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows. Keytruda (pembrolizumab) extended life four to eight months longer than chemotherapy in lung cancer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2018 Category: General Medicine Source Type: news